FDA-approved disulfiram as a novel treatment for aggressive leukemia

Mawar Karsa,Lin Xiao,Emma Ronca,Angelika Bongers,Dayna Spurling,Ayu Karsa,Sandra Cantilena,Anna Mariana,Tim W. Failes,Greg M. Arndt,Laurence C. Cheung,Rishi S. Kotecha,Rosemary Sutton,Richard B. Lock,Owen Williams,Jasper de Boer,Michelle Haber,Murray D. Norris,Michelle J. Henderson,Klaartje Somers

DOI: https://doi.org/10.1007/s00109-023-02414-4

2024-02-14

Journal of Molecular Medicine

Abstract:Acute leukemia continues to be a major cause of death from disease worldwide and current chemotherapeutic agents are associated with significant morbidity in survivors. While better and safer treatments for acute leukemia are urgently needed, standard drug development pipelines are lengthy and drug repurposing therefore provides a promising approach. Our previous evaluation of FDA-approved drugs for their antileukemic activity identified disulfiram, used for the treatment of alcoholism, as a candidate hit compound. This study assessed the biological effects of disulfiram on leukemia cells and evaluated its potential as a treatment strategy. We found that disulfiram inhibits the viability of a diverse panel of acute lymphoblastic and myeloid leukemia cell lines ( n = 16) and patient-derived xenograft cells from patients with poor outcome and treatment-resistant disease ( n = 15). The drug induced oxidative stress and apoptosis in leukemia cells within hours of treatment and was able to potentiate the effects of daunorubicin, etoposide, topotecan, cytarabine, and mitoxantrone chemotherapy. Upon combining disulfiram with auranofin, a drug approved for the treatment of rheumatoid arthritis that was previously shown to exert antileukemic effects, strong and consistent synergy was observed across a diverse panel of acute leukemia cell lines, the mechanism of which was based on enhanced ROS induction. Acute leukemia cells were more sensitive to the cytotoxic activity of disulfiram than solid cancer cell lines and non-malignant cells. While disulfiram is currently under investigation in clinical trials for solid cancers, this study provides evidence for the potential of disulfiram for acute leukemia treatment.

genetics & heredity,medicine, research & experimental

What problem does this paper attempt to address?

This paper attempts to solve several key problems in the treatment of acute leukemia:

1. **Improve the treatment effect of acute leukemia**: Acute leukemia remains one of the leading causes of death worldwide, especially for high - risk subtypes such as KMT2A - r rearranged (KMT2A - r) leukemia and relapsed T - cell acute lymphoblastic leukemia (T - ALL), with a survival rate of less than 50%. Although current chemotherapeutic drugs are effective, they have greater side effects on patients and their efficacy has reached the limit. Therefore, it is urgent to find safer and more effective treatment methods.

2. **Explore the possibility of new uses for old drugs**: Drug repurposing, as an alternative and efficient drug development approach, can accelerate the clinical application of new therapies. The paper mentions that disulfiram was originally used to treat alcohol dependence, but in previous studies it was found to have anti - leukemia activity, so it has become the focus of this study.

3. **Verify the effectiveness and mechanism of disulfiram as a potential treatment drug for acute leukemia**: The study aims to evaluate the impact of disulfiram on multiple acute leukemia cell lines and patient - derived xenograft cells, and explore its possible mechanism of action. Specifically, the study focuses on whether disulfiram can inhibit the growth of leukemia cells by inducing oxidative stress and apoptosis, and enhance the effect of existing chemotherapeutic drugs.

### Main findings of the study

- **Disulfiram has stronger cytotoxicity against acute leukemia cells**: Compared with solid tumor cells and non - malignant cells, disulfiram shows higher sensitivity to acute leukemia cells.

\[
IC_{50} \text{ values range from 45 to 81 nM}
\]

- **Disulfiram rapidly kills leukemia cells by inducing oxidative stress and apoptosis**: Within 6 hours, disulfiram significantly increased the intracellular ROS level and induced PARP cleavage, indicating that it induced apoptosis.

\[
\text{ROS level increased, cleaved PARP expression up - regulated}
\]

- **The combination of disulfiram and copper can enhance its anti - leukemia activity**: Although copper supplementation can further reduce the IC50 value of disulfiram, it also increases the toxicity to non - malignant cells, suggesting that the use of copper needs to be carefully evaluated.

- **Disulfiram has a synergistic effect when combined with standard chemotherapeutic drugs**: When disulfiram is combined with multiple chemotherapeutic drugs (such as daunorubicin, etoposide, cytarabine, mitoxantrone and topotecan), it shows a significant synergistic effect and can kill leukemia cells more effectively.

\[
\text{EOB Sum}>0, \text{ indicating the presence of a synergistic effect}
\]

### Conclusion

This study shows that disulfiram, as an FDA - approved drug, has potential anti - acute leukemia activity, especially when combined with other chemotherapeutic drugs, it shows a significant synergistic effect. These findings provide an important theoretical basis for the clinical trials of disulfiram in the treatment of acute leukemia.